Overview
Revuforj is approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute leukemia in people aged 1 year and older. It is used in two cases: for relapsed or refractory acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation, and for relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation (gene variation) when there are no satisfactory alternative treatment options. Revuforj is also known by its drug name, revumenib.

Revuforj is a menin inhibitor. It works by blocking a protein interaction that drives the growth of leukemia cells. This helps the cells develop more normally and may slow or stop the progression of the disease.

How do I take it?
Prescribing information states that Revuforj is taken orally twice daily, either fasted or with a low-fat meal, at approximately the same time each day.For those who tolerate the drug, at least six months of treatment is recommended to give time for a clinical response. Revuforj must be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Revuforj include nausea, hemorrhage (bleeding), increased phosphate levels, musculoskeletal pain, infections, elevated liver enzymes, febrile neutropenia (fever with low white blood cells), increased parathyroid hormone, bacterial infections, diarrhea, differentiation syndrome (a potentially severe complication), QT interval prolongation (a heart rhythm issue), decreased phosphate and potassium levels, increased triglycerides, decreased appetite, constipation, edema (swelling), viral infections, fatigue, and elevated alkaline phosphatase.

Rare but serious side effects may include differentiation syndrome, which can be fatal if not promptly treated, QT interval prolongation, and embryo-fetal toxicity (potential harm to unborn babies). People taking this medication should be monitored closely for these conditions, and females of reproductive potential should use effective contraception, according to the prescribing information.

For more information about this treatment, visit:

Revuforj (Revumenib) Tablets, for Oral Use — Syndax Pharmaceuticals